Home Cart Sign in  
Chemical Structure| 1001288-58-9 Chemical Structure| 1001288-58-9

Structure of FT011
CAS No.: 1001288-58-9

Chemical Structure| 1001288-58-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

FT011, an anti-fibrotic and an anti-inflammatory agent, prevents glycogen accumulation by reducing glycogenin mRNA translation.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of FT011

CAS No. :1001288-58-9
Formula : C20H17NO5
M.W : 351.35
SMILES Code : O=C(O)C1=CC=CC=C1NC(/C=C/C2=CC=C(OCC#C)C(OC)=C2)=O
MDL No. :MFCD28502026
InChI Key :UIWZIDIJCUEOMT-PKNBQFBNSA-N
Pubchem ID :23648966

Safety of FT011

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319
Precautionary Statements:P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Rat cardiac fibroblasts (RCF) 10 μM 12 hours To assess the inhibitory effect of FT011 on TGF-β1-induced cardiac fibroblast fibrosis. Results showed that FT011 significantly reduced the expression of α-SMA, collagen I, and collagen III. Mater Today Bio. 2025 May 14;32:101854
Müller cells 10, 30, 100 μM 72 hours To evaluate the effects of FT011M on hyperglycaemia-induced injury in Müller cells. FT011M reduced the hyperglycaemic-induced increase in MCP-1, sICAM-1, CCL20, GRO/CINC-1, VEGF, and IL-6 protein levels. PLoS One. 2015 Jul 29;10(7):e0134392

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Ren-2 rats Diabetic retinopathy model Intravitreal injection 50 μM 8-week and 32-week studies, with injections at 2 days and 4 weeks (8-week study) and at 16, 20, 24, and 28 weeks (32-week study) To evaluate the protective effects of FT011 on diabetic retinopathy. FT011 reduced retinal leukostasis, microglial density, ICAM-1 mRNA levels, Müller cell gliosis, VEGF immunolabeling, and the number of acellular capillaries. PLoS One. 2015 Jul 29;10(7):e0134392

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.85mL

0.57mL

0.28mL

14.23mL

2.85mL

1.42mL

28.46mL

5.69mL

2.85mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories